10X Genomics Inc

TXG is in a Stage 2 uptrend confirmed by steeply rising EMAs and an active Parabola pattern signaling aggressive trend acceleration. However, price is extreme overbought and extended well above the 9/20/50 EMAs, making immediate entries unfavorable. Medium-term bias remains bullish, with the preferred approach being to wait for pullbacks into the rising EMAs (9/20) for structural support and favorable risk/reward. A failure to hold these EMAs on a retracement would threaten the bullish stance.

• ↑EPS consensus revisions climbed 15.2% last three months, showing strong analyst sentiment
• ↑Collaborated with Lausanne University Hospital to advance cancer diagnostics
• ↓Q2 revenue dropped 12.7% YoY to $151M, hinting stagnation